Acerus Provides Update On Avanafil Health Canada Submission
TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that Health Canada has completed the initial screening…
Pharmaceuticals, Biotechnology and Life Sciences
TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that Health Canada has completed the initial screening…
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Coronary Artery Disease” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the…
PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today…
STAMFORD, Conn.–(BUSINESS WIRE)–SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases…
Company Will Prioritize Continued Development of Mirvetuximab Soravtansine and a Select Portfolio of Earlier-Stage Candidates Cash Runway Extended Through Readout…
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Hepatitis B” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Hepatitis…
Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community.
— Dr. Torsten Matthias appointed CEO, scientific founder Prof. Dr. Armin Giese joins as CSO —
— SERY technology in-licensed from Max-Planck Innovation GmbH to design next-generation candidate portfolio —
Agreement targets the development of a cross-reactive vaccine to protect against the most virulent enteroviruses, including enterovirus 71 (EV71)
Regeneron Pharmaceuticals and Sanofi got the approval from the FDA for Dupixent for certain combinations to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.